Core Insights - Inotiv, Inc. anticipates fourth quarter 2025 revenue between $137.5 million and $138.5 million, reflecting a year-over-year improvement and aligning with expectations [1][2] - The company expects full year 2025 revenue to be in the range of $512.5 million to $513.5 million [1][6] - The Discovery and Safety Assessment (DSA) services business experienced a 60% growth compared to the same period last year, with a book-to-bill ratio of approximately 1.08x for Q4 FY 2025 [2][6] Preliminary Financial Results - Preliminary expected revenue for Q4 FY 2025 is projected at $137.5 million to $138.5 million [1][6] - Full year 2025 revenue is anticipated to be between $512.5 million and $513.5 million [1][6] - DSA backlog is expected to be approximately $138.0 million as of September 30, 2025, an increase from $129.9 million a year prior [6] Company Presentation - Robert Leasure Jr., President and CEO, will present at the Jefferies Global Healthcare Conference on November 18, 2025, at 11:00 AM GMT [4] - The presentation will be accessible via a live webcast, with a replay available on the company's website [4] Company Overview - Inotiv, Inc. is a leading contract research organization focused on nonclinical and analytical drug discovery and development services [5][7] - The company aims to enhance efficiency, improve data quality, and reduce costs associated with bringing new drugs and medical devices to market [5]

Core Insights - Alpha Tau Medical Ltd. is participating in the Jefferies Global Healthcare Conference in London on November 18-19, 2025, where CFO Raphi Levy will hold 1x1 investor meetings [1] Company Overview - Alpha Tau Medical Ltd. was founded in 2016 and is an Israeli oncology therapeutics company focused on the research, development, and potential commercialization of Alpha DaRT for treating solid tumors [2] - The technology behind Alpha DaRT was developed by Prof. Itzhak Kelson and Prof. Yona Keisari from Tel Aviv University [2] Technology Details - Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) is designed for highly potent and conformal alpha-irradiation of solid tumors through intratumoral delivery of radium-224 impregnated sources [3] - The therapy works by releasing short-lived daughter isotopes from radium-224, which emit high-energy alpha particles aimed at destroying tumors while minimizing damage to surrounding healthy tissue [3]

Core Insights - Secura Bio, Inc. is participating in the Jefferies Global Healthcare Conference from November 17 to 20, 2025, in London, UK, with CEO Chip Romp and CFO Will Brown attending [1]. Company Overview - Secura Bio is an integrated, commercial-stage pharmaceutical company focused on the development and commercialization of impactful oncology therapies for healthcare providers and patients [2]. Investor and Media Contacts - Will Brown serves as the Chief Financial Officer and can be contacted at 619-986-1364 or via email at ir@securabio.com for investor inquiries [3]. - Media inquiries can be directed to Kit Rodophele at Ten Bridge Communications, reachable at 617-999-9620 or krodophele@tenbridgecommunications.com [3].

Core Insights - Shoulder Innovations, Inc. is set to present at the Jefferies Global Healthcare Conference on November 18, 2025, at 8:30 a.m. GMT / 3:30 a.m. EST [1][2] - The company focuses on transforming the shoulder surgical care market with advanced implant systems for shoulder arthroplasty [3] Company Overview - Shoulder Innovations is a commercial-stage medical technology company dedicated to improving shoulder surgical care through an ecosystem that includes preoperative planning, implant design, and procedural efficiency [3] - The company's offerings aim to address clinical and operational challenges in the shoulder surgical care market, delivering predictable outcomes and procedural simplicity [3] Upcoming Events - The live and archived version of the presentation will be available on the Investor Relations section of the Shoulder Innovations website [2]

Core Insights - Vivoryon Therapeutics N.V. is a clinical stage biotechnology company focused on developing small molecule medicines for inflammatory and fibrotic disorders, particularly kidney diseases [4] Conference Participation - The company will present at the American Society of Nephrology Kidney Week 2025 from November 5 to 9, 2025, in Houston, TX, USA, with a presentation titled "Correlation of eGFR and pE-CCL2 in Older Adult Patients Treated with Varoglutamstat: Data from VIVIAD, a Phase 2B Randomized Clinical Trial" scheduled for November 6 [2] - Additionally, the company will participate in 1x1 meetings at the Jefferies Global Healthcare Conference from November 18 to 20, 2025, in London, UK [3] - The company will also attend the Deutsches Eigenkapitalforum from November 24 to 26, 2025, in Frankfurt, Germany [3] Product Development - Vivoryon's leading program, varoglutamstat, is a proprietary, first-in-class orally available QPCT/L inhibitor being evaluated for the treatment of diabetic kidney disease [4]

Group 1 - The conference call features Stephen Hoge, President of Moderna, discussing the company's commercial business and pipeline developments [1] - There is a focus on the outlook for 2025, with particular attention to how changes in the administration may impact the business [2] - Moderna reaffirmed its revenue and cost guidance for the current year during the last quarterly call, indicating progress with the next-generation COVID vaccine approval, mRNA-1283 [3]

Company Overview - Viatris Inc. is actively participating in the Jefferies Global Healthcare Conference, with key executives including the Chief Financial Officer and Chief Commercial Officer present to discuss the company's performance and strategy [1]. Macro and Regulatory Environment - The CFO of Viatris acknowledges the evolving and dynamic market conditions, particularly in the generics sector, and emphasizes the importance of execution in the current year [2]. Financial Performance - Viatris reported solid first-quarter earnings, with sales meeting expectations across all segments, particularly noting operational growth in China and Europe. Excluding the impact from divestitures, the company achieved approximately 2% growth on a divestiture-adjusted operational basis [3].

Core Insights - Teva Pharmaceutical Industries Limited is focusing on growth through four key areas: innovative medicines, advancing its pipeline, strengthening its generics heritage, and concentrating business efforts and investments [3][4] - The company has experienced nine consecutive quarters of growth and is entering a new phase of acceleration projected between 2025 and 2027 [4] Business Evolution - The company has undergone significant changes over the past several years, with a strategic pivot to growth initiated in 2023 [3][4] - Investments have been made to enhance capabilities across the four identified pillars of growth [3] R&D Focus - Teva has set specific targets during its recent R&D Day, indicating a commitment to advancing its research and development initiatives [2]

Company Overview - Alpha Tau Medical Ltd. is an Israeli oncology therapeutics company founded in 2016, focusing on the research, development, and potential commercialization of the Alpha DaRT for treating solid tumors [3] - The technology behind Alpha DaRT was developed by Prof. Itzhak Kelson and Prof. Yona Keisari from Tel Aviv University [3] Product Information - Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) utilizes intratumoral delivery of radium-224 impregnated sources to provide highly potent and conformal alpha-irradiation of solid tumors [4] - The therapy aims to destroy tumors while sparing surrounding healthy tissue, as the alpha-emitting atoms diffuse only a short distance [4] Upcoming Events - The CFO of Alpha Tau, Raphi Levy, will present at the Jefferies Global Healthcare Conference on June 5, 2025, from 1:25 to 1:55 PM ET in New York, NY [2] - Mr. Levy will also be available for one-on-one investor meetings during the conference [2]

Group 1 - Sofwave Medical Ltd is an emerging leader in energy-based non-invasive aesthetic medical devices [1][2] - The company will present a corporate overview and participate in one-on-one investor meetings at the Jefferies Global Healthcare Conference from June 3-5, 2025 [1][2] - Assaf Korner, the Chief Financial Officer, will be representing the company at the conference [1] Group 2 - Sofwave Medical has developed proprietary technology called SUPERB™, which is FDA-cleared for improving facial lines, wrinkles, and skin laxity [2] - The company's Pure Impact™ module utilizes 4th generation EMS technology for muscle toning and is also FDA-cleared [2] - Sofwave's products are designed to provide effective and safe aesthetic solutions for physicians and their patients [2]